New drug shows promise for tough lung cancers
NCT ID NCT04940325
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests a new drug called DS-1062a in 100 people with advanced lung cancer that has not responded to other treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and look for markers that predict who will benefit most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre François Baclesse
Caen, 14076, France
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94010, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hospices Civils de Lyon - Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpital Tenon
Paris, 75970, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut de Cancérologie, CHRU Morvan de Brest
Brest, 29200, France
Conditions
Explore the condition pages connected to this study.